source
- Viking Therapeutics reports obesity drug maintains weight loss after dosing switch, shares jump 36%Viking Therapeutics said its Phase 2 trial of the dual-acting obesity candidate VK2735 showed participants largely kept the weight they had lost when the dosing schedule changed from a weekly injec…
- Celldex's barzolvolimab meets Phase 3 goals but safety concerns emergeCelldex announced that its experimental chronic hives treatment, barzolvolimab, achieved the primary endpoint in two Phase 3 trials. The trials demonstrated the drug's efficacy in reducing hive sy…